HIV-1 Entry and Membrane Fusion Inhibitors. PMID: 33922579
How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. PMID: 28422787
The env gene variability is not directly related to the high cytopathogenicity of an HIV1 variant. PMID: 2371777
Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability. PMID: 35692162
Sequencing the Biology of Entry: The Retroviral env Gene. PMID: 28688086
HIV-1 replication. PMID: 12465460
HIV-1 pseudoviruses constructed in China regulatory laboratory. PMID: 31859609
Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. PMID: 29212041
RRE-dependent HIV-1 Env RNA effects on Gag protein expression, assembly and release. PMID: 24971705
Reducing HIV-1 env gene CpG frequency increases the replication capacity of the HXB2 virus strain. PMID: 35041864
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. PMID: 21762802
Construction and Characterization of HIV-1 env-Pseudoviruses of the Recombinant Form CRF63_02A and Subtype A6. PMID: 35501651
Immunogenicity of HIV-1 envelope glycoprotein oligomers. PMID: 20048701
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. PMID: 34627310
HIV1 cytopathogenicity-genetic difference between direct cytotoxic and fusogenic effect. PMID: 1733106
Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression. PMID: 31431548
Structure of the transmembrane domain of HIV-1 envelope glycoprotein. PMID: 27868386
Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection. PMID: 35848590
HIV-1 Envelope FRETted Over by Antibodies. PMID: 31194935
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PMID: 27992602
[Revisiting HIV-1 assembly]. PMID: 18198110
AIDS virus envelope spike structure. PMID: 17395457
Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. PMID: 24937308
Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition. PMID: 34066522
Phylogenetics of HIV-1 subtype G env: Greater complexity and older origins than previously reported. PMID: 26190450
Dolutegravir inhibits HIV-1 Env evolution in primary human cells. PMID: 25849829
Recent advance in the structural analysis of HIV-1 envelope protein. PMID: 25921945
Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles. PMID: 30305355
Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones. PMID: 30415130
HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion. PMID: 30935048
Use of dual recombinant vaccinia virus vectors to assay viral glycoprotein-mediated fusion with transfection-resistant primary cell targets. PMID: 15114024
Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand. PMID: 19108694
Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time. PMID: 35372102
Functional and structural segregation of overlapping helices in HIV-1. PMID: 35511220
Reverted HIV-1 Mutants in CD4+ T-Cells Reveal Critical Residues in the Polar Region of Viral Envelope Glycoprotein. PMID: 34935422
High throughput functional analysis of HIV-1 env genes without cloning. PMID: 17416428
Genotypic tests for determining coreceptor usage of HIV-1. PMID: 21288812
Variations in Env at amino acids 328 and 330 affect HIV-1 replicative fitness and entry inhibitor sensitivity. PMID: 33862046
CpG Frequency in the 5' Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein. PMID: 31937644
Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks. PMID: 29300769
HIV Rev Assembly on the Rev Response Element (RRE): A Structural Perspective. PMID: 26075509
Centralized HIV-1 envelope immunogens and neutralizing antibodies. PMID: 18045113
HIV1 V3 loop hypermutability is enhanced by the guanine usage bias in the part of env gene coding for it. PMID: 20109155
Glucosidase inhibitors for treatment of HIV-1 infection. PMID: 1540404
Human immunodeficiency virus type 1-associated CD4 downmodulation. PMID: 7817874
Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes. PMID: 26324043
HIV-1 entry inhibitors: classes, applications and factors affecting potency. PMID: 17073614
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. PMID: 25589637
Morphogenesis of human immunodeficiency virus type 1. PMID: 1388714
Envelope glycoprotein mobility on HIV-1 particles depends on the virus maturation state. PMID: 28916807
Molecular strategies to design an escape-proof antiviral therapy. PMID: 21513746
Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected Thai individuals. PMID: 24513704
Appreciating HIV type 1 diversity: subtype differences in Env. PMID: 19327047
Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1. PMID: 33177204
Analysis of HIV-1 envelope cytoplasmic tail effects on viral replication. PMID: 36603533
The Changes of Positive Selection Within env Gene of HIV-1 B', CRF07_BC and CRF08_BC from China Over Time. PMID: 27917706
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. PMID: 9632381
Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. PMID: 30971821
Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. PMID: 28490588
Different HIV-1 env frames: gp120 and ASP (antisense protein) biosynthesis, and theirs co-variation tropic amino acid signatures in X4- and R5-viruses. PMID: 27328810
Virion attachment and entry: HIV gp120 Env biotinylation, gp120 Env, or integrin ligand-binding assay. PMID: 24158809
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. PMID: 19077194
HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. PMID: 16923919
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc. PMID: 27809912
Retromer regulates HIV-1 envelope glycoprotein trafficking and incorporation into virions. PMID: 25393110
Microsecond Dynamics and Network Analysis of the HIV-1 SOSIP Env Trimer Reveal Collective Behavior and Conserved Microdomains of the Glycan Shield. PMID: 28890362
HIV-1 mediated immune pathogenesis: spotlight on the role of viral protein R (Vpr). PMID: 19275586
Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. PMID: 28424455
Validation of HIV-1 MA Shell Structural Arrangements and Env Protein Interactions Predict a Role of the MA Shell in Viral Maturation. PMID: 37112873
Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. PMID: 26372275
The Vpr protein from HIV-1: distinct roles along the viral life cycle. PMID: 15725353
Mechanisms of infectivity and replication of HIV-1 and implications for therapy. PMID: 2178499
env Gene typing of human immunodeficiency virus type 1 strains on electronic microarrays. PMID: 15815017
Defective HIV-1 envelope gene promotes the evolution of the infectious strain through recombination in vitro. PMID: 32753067
Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein. PMID: 28283570
HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. PMID: 8800800
Genetic and Phenotypic Analysis of CRF01_AE HIV-1 env Clones from Patients Residing in Beijing, China. PMID: 27066910
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines., PMID:40438096
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366
Adaptor Protein Complexes in HIV-1 Pathogenesis: Mechanisms and Therapeutic Potential., PMID:40431726
Transmitted/founder (T/F) HIV-1 derived from sexual contact exhibits greater transmission fitness in human cervical tissue than T/F HIV-1 from blood-to-blood contact: Unique glycan profiles on T/F envelopes associated with transmission phenotypes., PMID:40408432
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning., PMID:40383778
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:40382314
Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms., PMID:40381660
Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies., PMID:40377318
Specific Interactions between HIV-1 Env Cytoplasmic Tail and Gag Matrix Domain Probed by NMR., PMID:40365918
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576
Threshold sensitivity analysis for HIV-1 transmission cluster detection using different genomic regions and subtypes., PMID:40327918
Analysis of Factors That Regulate HIV-1 Fusion in Reverse., PMID:40284914
Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains., PMID:40261015
The ectodomain sheddase ADAM10 restricts HIV-1 propagation and is counteracted by Nef., PMID:40249826
Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes., PMID:40239787
A monomeric envelope glycoprotein cytoplasmic tail is sufficient for HIV-1 Gag lattice trapping and incorporation., PMID:40231821
Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals., PMID:40207932
Distinctive Membrane Accommodation Traits Underpinning the Neutralization Activity of HIV-1 Antibody against MPER., PMID:40202993
Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques., PMID:40192306
Ab initio prediction of specific phospholipid complexes and membrane association of HIV-1 MPER antibodies by multi-scale simulations., PMID:40192122
ReaxFF-Guided Optimization of VIRIP-Based HIV-1 Entry Inhibitors., PMID:40178988
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns., PMID:40178906
Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope., PMID:40158219
A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120., PMID:40145736
Covariation of Amino Acid Substitutions in the HIV-1 Envelope Glycoprotein gp120 and the Antisense Protein ASP Associated with Coreceptor Usage., PMID:40143251
Host factor Naf1 restricts HIV-1 infection of myeloid cells and compromises the capacity of dendritic cell to prime CD4+ T cell., PMID:40139499
The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs., PMID:40089599
Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell-mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets., PMID:40086815
Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide., PMID:40063825
[Quercetin mitigates HIV-1 gp120-induced rat astrocyte neurotoxicity via promoting G3BP1 disassembly in stress granules]., PMID:40031974
Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy., PMID:40020046
Exploratory algorithms to devise multi-epitope subunit vaccine by examining HIV-1 envelope glycoprotein: An immunoinformatics and viroinformatics approach., PMID:40014623
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge., PMID:40007032
Inter-protomer opening cooperativity of envelope trimers positively correlates with HIV-1 entry stoichiometry., PMID:39998217
HIV-1 gp120 Interactions with Nicotine Modulate Mitochondrial Network Properties and Amyloid Release in Microglia., PMID:39992414
Versatile Features of an Antibody Mimetic Peptide and Its Variants., PMID:39962901
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264
Cysteines shape antibody battles for HIV-1 Env., PMID:39947129
Activation of CXCR3+ Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development., PMID:39932316
Conformational activation and disulfide exchange in HIV-1 Env induce cell-free lytic/fusogenic transformation and enhance infection., PMID:39912667
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development., PMID:39909038
High HIV-1 viremia and low anti-Env antibody responses are associated with delayed treatment response to fostemsavir in highly treatment-experienced individuals., PMID:39889907
Monovalent Lectin Microvirin Utilizes Hydropathic Recognition of HIV-1 Env for Inhibition of Virus Cell Infection., PMID:39861871
Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity., PMID:39836706
Current methods for detecting and assessing HIV-1 antibody resistance., PMID:39835119
Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage., PMID:39826122
Anti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens., PMID:39823319
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance., PMID:39817771
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth., PMID:39753033
For research use only. Not for human or drug use.
